Current trends in BSEP inhibition and perturbation to bile acid homeostasis as mechanisms of drug-induced liver injury
The Critical Path Institute’s Predictive Safety Testing Consortium hosted a webinar series focused on BSEP inhibition and perturbation to bile acid homeostasis as mechanisms of drug-induced liver injury.
Over the course of six two-hour webinars, scientists presented current data and research on clinical examples of BSEP inhibition and hepatotoxicity, in vivo tools for confirming perturbation to bile acid homeostasis, in vitro tools for identifying a BSEP liability in drug development programs, and the future direction for assessing BSEP inhibition. Each session concluded with an open discussion.
Series Organizers: Ryan Morgan, Amgen; Gerd Kullak-Ublick, Novartis; Jonathan Maher, Genentech, and John-Michael Sauer, Critical Path Institute
The first webinar was held on May 26, 2016 with the following sessions occurring until July 14, 2016. The webinars are available here to the public, for those unable to attend the sessions live.
You may register for the future sessions here: http://www.cvent.com/d/pfqr4n
Webinar Session Recordings
|Date||Session Title||Presentation Video|
|Thu, May 26, 2016||
Clinical examples of BSEP inhibition and hepatotoxicity
Clinical evidence of BSEP inhibition’s importance & current clinical perspective Gerd Kullak-Ublick (Novartis, University Hospital Zurich)
The AMG 009 Story: An opportunity to improve translational safety assessment Ryan Morgan (Amgen)
The Predictive Safety Testing Consortium (PSTC): LC-MS/MS bile acid profiling as a biomarker for BSEP inhibition Jonathan Maher (Genentech)
|Fri, June 3, 2016||Clinical examples of BSEP inhibition and hepatotoxicity & In vivo tools for confirming perturbation to bile acid homeostasis|
|Tue, June 7, 2016||In vivo tools for confirming perturbation to bile acid homeostasis|
|Wed, June 15, 2016||In vitro tools for identifying a BSEP liability|
|Fri, June 24, 2016||In vitro tools for identifying a BSEP liability|
|Thu, July 14, 2016||Future direction and next steps|